|
1
|
Lu X and Kang Y: Hypoxia and
hypoxia-inducible factors: Master regulators of metastasis. Clin
Cancer Res. 16:5928–5935. 2010.
|
|
2
|
Ye J, Wu D, Wu P, Chen Z and Huang J: The
cancer stem cell niche: Cross talk between cancer stem cells and
their microenvironment. Tumour Biol. 35:3945–3951. 2014.
|
|
3
|
Carmeliet P: VEGF as a key mediator of
angiogenesis in cancer. Oncology. 69(Suppl 3): S4–S10. 2005.
|
|
4
|
Semenza GL: Hypoxia-inducible factor 1 and
the molecular physiology of oxygen homeostasis. J Lab Clin Med.
131:207–214. 1998.
|
|
5
|
Semenza GL: HIF-1 and human disease: One
highly involved factor. Genes Dev. 14:1983–1991. 2000.
|
|
6
|
Bertout JA, Patel SA and Simon MC: The
impact of O2 availability on human cancer. Nat Rev
Cancer. 8:967–975. 2008.
|
|
7
|
Clerici C and Planès C: Gene regulation in
the adaptive process to hypoxia in lung epithelial cells. Am J
Physiol Lung Cell Mol Physiol. 296:L267–L274. 2009.
|
|
8
|
Fotsis T, Zhang Y, Pepper MS, Adlercreutz
H, Montesano R, Nawroth PP and Schweigerer L: The endogenous
oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and
suppresses tumour growth. Nature. 368:237–239. 1994.
|
|
9
|
Becker CM, Rohwer N, Funakoshi T, Cramer
T, Bernhardt W, Birsner A, Folkman J and D'Amato RJ:
2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and
suppresses growth of lesions in a mouse model of endometriosis. Am
J Pathol. 172:534–544. 2008.
|
|
10
|
Escuin D, Kline ER and Giannakakou P: Both
microtubule-stabilizing and microtubule-destabilizing drugs inhibit
hypoxia-inducible factor-1alpha accumulation and activity by
disrupting microtubule function. Cancer Res. 65:9021–9028.
2005.
|
|
11
|
Chua YS, Chua YL and Hagen T: Structure
activity analysis of 2-methoxyestradiol analogues reveals targeting
of microtubules as the major mechanism of antiproliferative and
proapoptotic activity. Mol Cancer Ther. 9:224–235. 2010.
|
|
12
|
D'Amato RJ, Lin CM, Flynn E, Folkman J and
Hamel E: 2-Methoxyestradiol, an endogenous mammalian metabolite,
inhibits tubulin polymerization by interacting at the colchicine
site. Proc Natl Acad Sci USA. 91:3964–3968. 1994.
|
|
13
|
Benedikt MB, Mahlum EW, Shogren KL,
Subramaniam M, Spelsberg TC, Yaszemski MJ and Maran A:
2-methoxyestradiol-mediated anti-tumor effect increases
osteoprotegerin expression in osteosarcoma cells. J Cell Biochem.
109:950–956. 2010.
|
|
14
|
Bu S, Blaukat A, Fu X, Heldin NE and
Landström M: Mechanisms for 2-methoxyestradiol-induced apoptosis of
prostate cancer cells. FEBS Lett. 531:141–151. 2002.
|
|
15
|
Rankin EB and Giaccia AJ: The role of
hypoxia-inducible factors in tumorigenesis. Cell Death Differ.
15:678–685. 2008.
|
|
16
|
Kilic M, Kasperczyk H, Fulda S and Debatin
KM: Role of hypoxia inducible factor-1 alpha in modulation of
apoptosis resistance. Oncogene. 26:2027–2038. 2007.
|
|
17
|
Sermeus A, Cosse JP, Crespin M, Mainfroid
V, de Longueville F, Ninane N, Raes M, Remacle J and Michiels C:
Hypoxia induces protection against etoposide-induced apoptosis:
Molecular profiling of changes in gene expression and transcription
factor activity. Mol Cancer. 7:272008.
|
|
18
|
Yu EZ, Li YY, Liu XH, Kagan E and McCarron
RM: Antiapoptotic action of hypoxia-inducible factor-1 alpha in
human endothelial cells. Lab Invest. 84:553–561. 2004.
|
|
19
|
Mabjeesh NJ, Escuin D, LaVallee TM,
Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW
and Giannakakou P: 2ME2 inhibits tumor growth and angiogenesis by
disrupting microtubules and dysregulating HIF. Cancer Cell.
3:363–375. 2003.
|
|
20
|
Brown JM and Wilson WR: Exploiting tumour
hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004.
|
|
21
|
Flamant L, Notte A, Ninane N, Raes M and
Michiels C: Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel
exposed breast cancer cells under hypoxia. Mol Cancer.
9:1912010.
|
|
22
|
Sun HC, Qiu ZJ, Liu J, Sun J, Jiang T,
Huang KJ, Yao M and Huang C: Expression of hypoxia-inducible
factor-1 alpha and associated proteins in pancreatic ductal
adenocarcinoma and their impact on prognosis. Int J Oncol.
30:1359–1367. 2007.
|
|
23
|
Swinson DE, Jones JL, Cox G, Richardson D,
Harris AL and O'Byrne KJ: Hypoxia-inducible factor-1 alpha in non
small cell lung cancer: Relation to growth factor, protease and
apoptosis pathways. Int J Cancer. 111:43–50. 2004.
|
|
24
|
Kuo KL, Lin WC, Ho IL, Chang HC, Lee PY,
Chung YT, Hsieh JT, Pu YS, Shi CS and Huang KH: 2-methoxyestradiol
induces mitotic arrest, apoptosis, and synergistic cytotoxicity
with arsenic trioxide in human urothelial carcinoma cells. PLoS
One. 8:e687032013.
|
|
25
|
Zhou NN, Zhu XF, Zhou JM, Li MZ, Zhang XS,
Huang P and Jiang WQ: 2-Methoxyestradiol induces cell cycle arrest
and apoptosis of nasopharyngeal carcinoma cells. Acta Pharmacol
Sin. 25:1515–1520. 2004.
|
|
26
|
Rajkumar SV, Richardson PG, Lacy MQ,
Dispenzieri A, Greipp PR, Witzig TE, Schlossman R, Sidor CF,
Anderson KC and Gertz MA: Novel therapy with 2-methoxyestradiol for
the treatment of relapsed and plateau phase multiple myeloma. Clin
Cancer Res. 13:6162–6167. 2007.
|
|
27
|
Sweeney C, Liu G, Yiannoutsos C, Kolesar
J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, et
al: A phase II multicenter, randomized, double-blind, safety trial
assessing the pharmacokinetics, pharmacodynamics, and efficacy of
oral 2-methoxyestradiol capsules in hormone-refractory prostate
cancer. Clin Cancer Res. 11:6625–6633. 2005.
|
|
28
|
James J, Murry DJ, Treston AM, Storniolo
AM, Sledge GW, Sidor C and Miller KD: Phase I safety,
pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol
alone or in combination with docetaxel in patients with locally
recurrent or metastatic breast cancer. Invest New Drugs. 25:41–48.
2007.
|
|
29
|
Matei D, Schilder J, Sutton G, Perkins S,
Breen T, Quon C and Sidor C: Activity of 2 methoxyestradiol (Panzem
NCD) in advanced, platinum-resistant ovarian cancer and primary
peritoneal carcinomatosis: A Hoosier Oncology Group trial. Gynecol
Oncol. 115:90–96. 2009.
|
|
30
|
Bottsford-Miller JN, Coleman RL and Sood
AK: Resistance and escape from antiangiogenesis therapy: Clinical
implications and future strategies. J Clin Oncol. 30:4026–4034.
2012.
|
|
31
|
Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang
X, Li J, Qiao H, Ni S and Sun X: 2-Methoxyestradiol synergizes with
sorafenib to suppress hepatocellular carcinoma by simultaneously
dysregulating hypoxia-inducible factor-1 and -2. Cancer Lett.
355:96–105. 2014.
|
|
32
|
Semenza GL: Evaluation of HIF-1 inhibitors
as anticancer agents. Drug Discov Today. 12:853–859. 2007.
|
|
33
|
Harris AL: Hypoxia - a key regulatory
factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002.
|
|
34
|
Teicher BA, Holden SA, al-Achi A and
Herman TS: Classification of antineoplastic treatments by their
differential toxicity toward putative oxygenated and hypoxic tumor
subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer
Res. 50:3339–3344. 1990.
|
|
35
|
Mueck AO and Seeger H: 2-Methoxyestradiol
- biology and mechanism of action. Steroids. 75:625–631. 2010.
|
|
36
|
Piret JP, Mottet D, Raes M and Michiels C:
Is HIF-1alpha a pro-or an anti-apoptotic protein? Biochem
Pharmacol. 64:889–892. 2002.
|
|
37
|
Greijer AE and van der Wall E: The role of
hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J
Clin Pathol. 57:1009–1014. 2004.
|
|
38
|
Shen H, Yang Y, Xia S, Rao B, Zhang J and
Wang J: Blockage of Nrf2 suppresses the migration and invasion of
esophageal squamous cell carcinoma cells in hypoxic
microenvironment. Dis Esophagus. 27:685–692. 2014.
|
|
39
|
Visagie MH and Joubert AM: In vitro
effects of 2-methoxyestra-diol-bis-sulphamate on reactive oxygen
species and possible apoptosis induction in a breast adenocarcinoma
cell line. Cancer Cell Int. 11:432011.
|
|
40
|
Stander BA, Marais S, Vorster CJ and
Joubert AM: In vitro effects of 2-methoxyestradiol on morphology,
cell cycle progression, cell death and gene expression changes in
the tumorigenic MCF-7 breast epithelial cell line. J Steroid
Biochem Mol Biol. 119:149–160. 2010.
|
|
41
|
Vorster C and Joubert A: In vitro effects
of 2-methoxyestradiol-bis-sulphamate on cell growth, morphology and
cell cycle dynamics in the MCF-7 breast adenocarcinoma cell line.
Biocell. 34:71–79. 2010.
|
|
42
|
Chander SK, Foster PA, Leese MP, Newman
SP, Potter BV, Purohit A and Reed MJ: In vivo inhibition of
angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol.
Br J Cancer. 96:1368–1376. 2007.
|
|
43
|
Tevaarwerk AJ, Holen KD, Alberti DB, Sidor
C, Arnott J, Quon C, Wilding G and Liu G: Phase I trial of
2-methoxyestra-diol NanoCrystal dispersion in advanced solid
malignancies. Clin Cancer Res. 15:1460–1465. 2009.
|
|
44
|
Visagie M, Theron A, Mqoco T, Vieira W,
Prudent R, Martinez A, Lafanechère L and Joubert A: Sulphamoylated
2-methoxyestra-diol analogues induce apoptosis in adenocarcinoma
cell lines. PLoS One. 8:e719352013.
|
|
45
|
Ricker JL, Chen Z, Yang XP, Pribluda VS,
Swartz GM and Van Waes C: 2-methoxyestradiol inhibits
hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and
augments paclitaxel efficacy in head and neck squamous cell
carcinoma. Clin Cancer Res. 10:8665–8673. 2004.
|
|
46
|
Sato M, Tanaka T, Maeno T, Sando Y, Suga
T, Maeno Y, Sato H, Nagai R and Kurabayashi M: Inducible expression
of endothelial PAS domain protein-1 by hypoxia in human lung
adenocarcinoma A549 cells. Role of Src family kinases-dependent
pathway. Am J Respir Cell Mol Biol. 26:127–134. 2002.
|
|
47
|
Uchida T, Rossignol F, Matthay MA, Mounier
R, Couette S, Clottes E and Clerici C: Prolonged hypoxia
differentially regulates hypoxia-inducible factor (HIF)-1alpha and
HIF-2alpha expression in lung epithelial cells: Implication of
natural antisense HIF-1alpha. J Biol Chem. 279:14871–14878.
2004.
|
|
48
|
Wu XH, Qian C and Yuan K: Correlations of
hypoxia-inducible factor-1α/hypoxia-inducible factor-2α expression
with angio-genesis factors expression and prognosis in non-small
cell lung cancer. Chin Med J. 124:11–18. 2011.
|
|
49
|
Kim WY, Perera S, Zhou B, Carretero J, Yeh
JJ, Heathcote SA, Jackson AL, Nikolinakos P, Ospina B, Naumov G, et
al: HIF2α cooperates with RAS to promote lung tumorigenesis in
mice. J Clin Invest. 119:2160–2170. 2009.
|
